Anzeige
Mehr »
Samstag, 14.02.2026 - Börsentäglich über 12.000 News
20 Mio. € Bewertung. Zwei zugelassene Psychedelika-Produkte. NASDAQ-Uplist in Arbeit.
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
ACCESS Newswire
316 Leser
Artikel bewerten:
(1)

Physitrack PLC - Interim Report: January - March 2022

LONDON, GB / ACCESSWIRE / May 25, 2022 / Physitrack (STO:PTRK)

"Growth trajectory continues"

Quarter ended 31 March 2022 (January - March 2022)

  • Revenue increased by 67 per cent from the comparative period in 2021 to generate total sales of EUR 2.6m (EUR 1.5m). On a proforma basis revenue grew by 29 per cent. This increase was primarily driven through an increase in subscribers on the SaaS platform and continued focus by management on retention, reducing churn.
  • Adjusted EBITDA increased by 44 per cent from the comparative period in 2021 to EUR 0.7m (EUR 0.5m), resulting in an Adjusted EBITDA margin of 29 percent (34 per cent). The movement from the prior year comparative was driven by recent acquisitions, as well as the Group's current focus on ensuring that the underlying business is structured, with the right systems and processes to support its scale-up ambitions.
  • Adjusted operating profit of EUR 0.4m (EUR 0.2m) was generated resulting in a margin of 17 per cent (13 per cent) driven by a fall in amortisation due to the amortisation period of certain historic assets ending.
  • Adjusted ordinary and diluted earnings per share totalled EUR 0.02 (EUR 0.02).
  • Cashflow generated from operations before the payment of adjusting items equalled EUR 0.5m (EUR 0.5m).
  • Following the closure of the period, Physitrack acquired Champion Health, a leading UK digital workplace health platform, to capture stronghold in corporate wellness market and enhance its holistic care offering. Learn more about Champion Health and the acquisition at https://vimeo.com/713136708/54fc934c6b.

Henrik Molin, Co-founder and CEO of Physitrack PLC commented:
"As we build on the success of the 2021 financial year, I am pleased to see the continuation of the Group's growth trajectory in 2022 coupled with significantly accelerating EBITDA. As outlined within the IPO prospectus, the Group is building on the success of the existing SaaS platform and utilising this stable and financially successful foundation to develop and build a corporate virtual wellness ecosystem. As a result of the acquisitions which have taken place during and subsequent to Q1 2022 we now have the building blocks of an all-encompassing Virtual Wellness offering and larger geographic footprint in key markets. I am excited to see this grow during the financial year."

Webcast conference
A webcast and telephone conference will be held at 10.00 a.m. CEST today with CEO Henrik Molin and CFO Charlotte Goodwin. The presentation will be held in English and will be available on https://www.physitrackgroup.com/investors/reports-presentations after the webcast conference.

Dial-in number for teleconference:
SE: +46850558374
UK: +443333009263
US: +16319131422
PIN: 11026918#

Link to webcast:
https://tv.streamfabriken.com/physitrack-group-q1-2022

Enquiries regarding this announcement should be addressed to:
Adam Nilsson, investor and media contact, Physitrack:
+46 (0) 707 46 44 21
ir@physitrack.com
media@physitrack.com

About Physitrack
Physitrack PLC, founded in 2012, is a global digital healthcare provider, focused on the B2B wellness and virtual-first care markets. With staff on four continents, customers in 17 time zones, and end users in 187 countries, Physitrack is a truly global company.

The company has two business lines:

1. Software-as-a-Service (SaaS) - based software platform tailored mainly to physiotherapy and musculoskeletal care, enabling practitioners to deliver clinical home exercises, education prescription, outcomes tracking, triaging and Telehealth.
2. Virtual-first wellness and care provision powered by the Physitrack technology platform and care professionals based in the United Kingdom, Germany and the Nordics.

Physitrack PLC is headquartered in London, United Kingdom, and listed on Nasdaq First North Premier Growth Market (PTRK).

Visit us at https://www.physitrackgroup.com/.

Certified Advisor
FNCA Sweden AB is the appointed Certified Adviser of Physitrack.
info@fnca.se, +46 8 528 00 399

This information is information that Physitrack is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2022-05-25 08:00 CEST.

Attachments

Physitrack PLC - Interim Report, January - March 2022

SOURCE: Physitrack



View source version on accesswire.com:
https://www.accesswire.com/702642/Physitrack-PLC-Interim-Report-January-March-2022

© 2022 ACCESS Newswire
Favoritenwechsel - diese 5 Werte sollten Anleger im Depot haben!
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.